26 related articles for article (PubMed ID: 12182053)
1. Modeling the effect of levothyroxine therapy on bone mass density in postmenopausal women: a different approach leads to new inference.
Mohammadi B; Haghpanah V; Tavangar SM; Larijani B
Theor Biol Med Model; 2007 Jun; 4():23. PubMed ID: 17559682
[TBL] [Abstract][Full Text] [Related]
2. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
[TBL] [Abstract][Full Text] [Related]
4. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.
Görres G; Kaim A; Otte A; Götze M; Müller-Brand J
Eur J Nucl Med; 1996 Jun; 23(6):690-2. PubMed ID: 8662104
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of bone density in women after thyroid cancer surgery and treatment with suppressive doses of L-thyroxine].
Jurecka-Tuleja B; August R; Kukulska A; Bartnikowa W; Deja R; Czernik E; Handkiewicz-Junak D
Wiad Lek; 2001; 54 Suppl 1():378-82. PubMed ID: 12182053
[TBL] [Abstract][Full Text] [Related]
8. [Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine].
Jastrzebska H; Gietka-Czernel M; Zgliczyński S
Wiad Lek; 2001; 54 Suppl 1():383-8. PubMed ID: 12182054
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature.
Quan ML; Pasieka JL; Rorstad O
J Surg Oncol; 2002 Jan; 79(1):62-9; discussion 69-70. PubMed ID: 11754378
[TBL] [Abstract][Full Text] [Related]
10. [Treatment with L-thyroxine for differentiated thyroid carcinoma].
Łacka K
Wiad Lek; 2001; 54 Suppl 1():368-72. PubMed ID: 12182051
[TBL] [Abstract][Full Text] [Related]
11. Thyroid function and postmenopause.
Schindler AE
Gynecol Endocrinol; 2003 Feb; 17(1):79-85. PubMed ID: 12724022
[TBL] [Abstract][Full Text] [Related]
12. [Osteoporosis in thyroid diseases].
Kosińska A; Syrenicz A; Kosiński B; Garanty-Bogacka B; Syrenicz M; Gromniak E
Endokrynol Pol; 2005; 56(2):185-93. PubMed ID: 16335687
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
